Exane Derivatives’s Novo Nordisk NVO Stock Holding History

Exane Derivatives’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$3.23K	Hold	58	–	–	﹤0.01%	409
2022 Q1	$3.22K	Hold	58	–	–	﹤0.01%	724
2021 Q4	$3.25K	Hold	58	–	–	﹤0.01%	639
2021 Q3	$2.78K	Hold	58	–	–	﹤0.01%	779
2021 Q2	$2.51K	Hold	58	–	–	﹤0.01%	804
2021 Q1	$1.96K	Hold	58	–	–	﹤0.01%	680
2020 Q4	$2.03K	Hold	58	–	–	﹤0.01%	625
2020 Q3	$2.01K	Hold	58	–	–	﹤0.01%	564
2020 Q2	$1.9K	Hold	58	–	–	﹤0.01%	508
2020 Q1	$1.75K	Hold	58	–	–	﹤0.01%	509
2019 Q4	$1.81K	Hold	58	–	–	﹤0.01%	502
2019 Q3	$1.5K	Hold	58	–	–	﹤0.01%	512
2019 Q2	$1.48K	Hold	58	–	–	﹤0.01%	532
2019 Q1	$1.52K	Hold	58	–	–	﹤0.01%	473
2018 Q4	$1.34K	Hold	58	–	–	﹤0.01%	555
2018 Q3	$1.37K	Hold	58	–	–	﹤0.01%	519
2018 Q2	$1.34K	Hold	58	–	–	﹤0.01%	512
2018 Q1	$1.43K	Sell	58 -104	-64%	-$2.73K	﹤0.01%	464
2017 Q4	$4.35K	Sell	162 -490	-75%	-$12.5K	﹤0.01%	431
2017 Q3	$15.7K	Sell	652 -182	-22%	-$4.11K	﹤0.01%	366
2017 Q2	$17.9K	Hold	834	–	–	﹤0.01%	368
2017 Q1	$14.3K	Sell	834 -1,066	-56%	-$18.6K	﹤0.01%	341
2016 Q4	$34.1K	Hold	1,900	–	–	0.01%	323
2016 Q3	$39.5K	Sell	1,900 -1,150	-38%	-$28.5K	0.01%	321
2016 Q2	$82K	Sell	3,050 -62	-2%	-$1.7K	0.01%	250
2016 Q1	$84.3K	Buy	3,112 +314	+11%	+$8.41K	0.01%	258
2015 Q4	$81.2K	Buy	2,798 +1,348	+93%	+$37.3K	0.01%	228
2015 Q3	$39.3K	Buy	1,450 +1,248	+618%	+$35.3K	0.01%	289
2015 Q2	$5.53K	Sell	202 -3,492	-95%	-$98.2K	﹤0.01%	390
2015 Q1	$98.6K	Buy	+3,694	New	+$85.1K	0.01%	266

Other funds holding NVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Exane Derivatives's NVO Position: Q2 2022 in Review

Exane Derivatives held its Novo Nordisk (NVO) position steady in Q2 2022 at 58 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #409.

Exane Derivatives first reported a position in NVO in Q1 2015 and has held it in 30 quarters since. The position peaked at $98.6K in Q1 2015. 932 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

Exane Derivatives held 58 shares of Novo Nordisk worth $3.23K as of Q2 2022.
Exane Derivatives left its Novo Nordisk share count unchanged in Q2 2022.
Novo Nordisk made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #409 holding.
Exane Derivatives first reported a position in Novo Nordisk in Q1 2015 and has held it in 30 quarters since.
Exane Derivatives's Novo Nordisk position peaked at $98.6K in Q1 2015.
932 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.